Business Description
Fate Therapeutics Inc
NAICS : 325412
SIC : 2836
Compare
Compare
Traded in other countries / regions
F6T.GermanyFATE.USA Description
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.55 | |||||
| Equity-to-Asset | 0.69 | |||||
| Debt-to-Equity | 0.21 | |||||
| Debt-to-EBITDA | -0.37 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -0.65 | |||||
| Beneish M-Score | -3.06 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 91.4 | |||||
| 3-Year EBITDA Growth Rate | -24.3 | |||||
| 3-Year EPS without NRI Growth Rate | -23.5 | |||||
| 3-Year FCF Growth Rate | -45.7 | |||||
| 3-Year Book Growth Rate | 41.9 | |||||
| Future 3-5Y Total Revenue Growth Rate | 20.76 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 68.31 | |||||
| 9-Day RSI | 54.03 | |||||
| 14-Day RSI | 42.55 | |||||
| 6-1 Month Momentum % | -88.56 | |||||
| 12-1 Month Momentum % | -88.33 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.15 | |||||
| Quick Ratio | 5.15 | |||||
| Cash Ratio | 4.86 | |||||
| Days Sales Outstanding | 56.26 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -14 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -454.04 | |||||
| Net Margin % | -425.98 | |||||
| ROE % | -46.8 | |||||
| ROA % | -34.02 | |||||
| ROIC % | -108.8 | |||||
| ROC (Joel Greenblatt) % | -188.74 | |||||
| ROCE % | -39.81 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 9.57 | |||||
| PB Ratio | 1.28 | |||||
| Price-to-Tangible-Book | 1.26 | |||||
| EV-to-EBIT | -0.88 | |||||
| EV-to-EBITDA | -0.91 | |||||
| EV-to-Revenue | 3.92 | |||||
| EV-to-Forward-Revenue | 4.06 | |||||
| EV-to-FCF | -0.93 | |||||
| Price-to-Net-Current-Asset-Value | 2.15 | |||||
| Price-to-Net-Cash | 2.39 | |||||
| Earnings Yield (Greenblatt) % | -113.64 |
How Fate Therapeutics Inc (FRA:F6T) Makes Its Money
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Executives
Details
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 64.504 | ||
| EPS (TTM) (€) | -2.87 | ||
| Beta | 0.95 | ||
| Volatility % | 79.77 | ||
| 14-Day RSI | 42.55 | ||
| 14-Day ATR (€) | 0.396927 | ||
| 20-Day SMA (€) | 5.440675 | ||
| 12-1 Month Momentum % | -88.33 | ||
| 52-Week Range (€) | 3.8555 - 38.42 | ||
| Shares Outstanding (Mil) | 97.17 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Fate Therapeutics Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Fate Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||